SEC Form 4 · accession 0001209191-19-000585
Alaunos Therapeutics, Inc. · TCRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Anthony Cannon
Director
Period of report
Dec 29, 2018
Accepted (ET)
Jan 2, 2019 · 9:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001107421
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 29, 2018 | F | 4,315 | $1.66 | D | 383,050 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $1.87 | Dec 31, 2018 | A | 126,700 | A | — | Dec 31, 2028 | Common Stock | 126,700 | 126,700 | D |
Explanation of responses
- F1Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grants.
- F2126,700 options vest on 12/31/2019.